Plasma homocysteine, apolipoprotein e status and vascular disease in elderly patients with mental illness

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 1, 2010, Pages 129-135

  Nilsson, Karin ^a   Gustafson, Lars ^a   Nornholm, Michael ^a   Hultberg, Björn ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apolipoprotein E; Cobalamin; Creatinine; Folate; Homocysteine; Psychogeriatric patients; Vascular disease

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; HOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; BRAIN INFARCTION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ALLELES; APOLIPOPROTEINS E; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; VASCULAR DISEASES;

EID: 74549186458     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.013     Document Type: Article

References (48)

1. Mahley RW, Rall SC. Apolipoprotein E. Far more than a lipid transport protein. Annu Rev Genom Hum G 2000;1:507-537
2. Eichner JE, Dunn ST, Perveen GP, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a huge review. Am J Epidemiol 2002;155:487-495
3. Poirer J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005;26:355-361
4. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis; insight from animal and human studies. Clin Chim Acta 1999;286:115-143
5. Nilsson K, Gustafson L, Fädt R, Andersson A, Brattströ L, Lindgren A, et al. Hyperhomocysteinemia-a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26: 853-859
6. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455
7. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn 1999;10:12-20.
8. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate and vitamin B-12 in mild cognitive impairment, Alzheimer's disease and vascular dementia. Am J Clin Nutr 2004;80:114-122
9. Refsum H, Smith DA, Ueland PM, NexöE, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
10. Brattströ L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236: 633-641
11. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002:325;1202-1209
12. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. J Am Med Assoc 2002;288:2015-2022
13. Wald DS, Morris JK, Law M, Wald NJ. Folic acid, homocysteine and cardiovascular disease: judging causality in the face of inconclusive trial evidence. Br Med J 2006;333:1114-1117
14. Herrmann W. Homocysteine research: alive and kicking! Clin Chem Lab Med 2007;45:1571-1574
15. Ueland PM, Clarke R. Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power. Clin Chem 2007;53:807-809
16. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inher Metab Dis 2006;29:3-20.
17. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration and its relation to symptoms of vascular disease in psychogeriatric patients. Dement Geriatr Cogn 2005;20:5-41.
18. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine and vascular disease in elderly patients with psychogeriatric disease. Dement Geriatr Cogn 2006;21:148-154
19. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine, cobalamin/folate status, and vascular disease in a large population of psychogeriatric patients. Dement Geriatr Cogn 2006: 22:358-366
20. Nilsson K, Gustafson L, Hultberg B. Elevated plasma homocysteine concentration in elderly patients with mental illness is mainly related to the presence of vascular disease and not the diagnosis. Dement Geriatr Cogn 2007;24:162-168
21. Alagiakrishnan A, McCracen P, Feldman H. Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad Med J 2006;82:101-105
22. Mielke MM, Zandi PP. Hematologic risk factors of vascular disease and their relation to dementia. Dement Geriatr Cogn 2006;21:335-52.
23. Brun A. The neuropathology of vascular dementia and its overlap with Alzheimer's disease. In: O'Brien J, Ames D, Gustafson L, Folstein M, Chiu E, editors. Cerebrovascular disease, cognitive impairment and dementia, 2nd ed. Martin Dunitz: Taylor & Francis Group, 2004:103-115
24. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145 (Pubitemid 126512042)
25. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis apolipoprotein E, and prevalence of dementia and Alzheimers disease in the Rotterdam Study. Lancet 1997;349:151-154 (Pubitemid 27039193)
26. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and risk of dementia: the Rotterdam Study. Neurology 1999;53:1937-1942
27. Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol 2007;16: 143-149
28. Korczyn AD. The underdiagnosis of the vascular contribution to dementia. J Neurol Sci 2005;229-230:3-6.
29. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine and vascular disease in elderly patients with mental illness. Clin Chem Lab Med 2008;46:1556-1561
30. Nilsson K, Gustafson L, Hultberg B. Homocysteine, cystatin C and N-terminal-pro brain natriuretic peptide. Vascular risk markers in elderly patients with mental illness. Dement Geriatr Cogn 2007;25:88-96.
31. Nilsson K, Gustafson L, Hultberg B. C-reactive protein-vascular risk marker in elderly patients with mental illness. Dement Geriatr Cogn 2008;26:251-256
32. American Psychiatric Association. DSM IV. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
33. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International workshop. Neurology 1993;43:250-260
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
35. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308 (Pubitemid 29120227)
36. Andersson A, Isaksson A, Brattströ L, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific post-column derivatization. Clin Chem 1993; 39:1590-1597
37. Hixson JE. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arterioscler Thromb 1991;11:1237-1244
38. Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglumd L. Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem 1993;39:2125-2129
39. Religa D, Styczynska M, Peplonska B, Gabryelewicz T, Pfeffer A, Chodakowaska M, et al. Homocysteine, apolipoprotein E and methyleneterahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn 2003; 16:64-70.
40. Lin SK, Kao JT, Tsai SM. Association of apolipoprotein E genotypes with serum lipid profiles in a healthy population of Taiwan. Am Clin Lab Sci 2004;34:443-448
41. Elias MF, Robbins MA, Budge MM, Elias PK, Dore GA, Brennan SL, et al. Homocysteine and cognitive performance: modification by the ApoE genotype. Neurosci Lett 2008;430:4-69.
42. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Bianchin M, et al. Apolipoprotein E e4 allele affects risk of hyperhomocysteinemia in the elderly. Am J Clin Nutr 2006;84: 1473-1480
43. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Hayden KM, Norton M, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69:1850-1858
44. Song IU, Kim JS, Eah KY, Lee KS. Clinical significance of silent cerebral infarctions in patients with Alzheimer disease. Cogn Behav Neurol 2007;20:93-98
45. Sheng B, Cheng LF, Law CB, Li HL, Yeung KM, Lau KK. Coexisting cerebral infarction in Alzheimer's disease is associated with fast dementia progression: applying the National Institute for Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences Neuroimaging Criteria in Alzheimer's Disease with Concomitant Cerebral Infarction. J Am Geriatr Soc 2007;55: 918-922
46. Mahley RW, Huang Y, Weisgraber KH. Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2007;4:537-540
47. Baum L, Lam LC, Kwok T, Lee J, Chiu HF, Mok VC, et al. Apolipoprotein E 4 allele is associated with vascular dementia. Dement Geriatr Cogn 2006;22:301-305
48. Bretsky P, Guralnik L, Launer L, Albert M, Seeman TE. The role of ApoE-epsilon 4 in longitudinal cognitive decline: Mac- Arthur studies of successful aging. Neurology 2003;60:1077-1081